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Abstract
Background: Curcumin induces apoptosis in many cancer cells and it reduces xenograft growth
and the formation of lung metastases in nude mice. Moreover, the plant derived polyphenol has
been reported to be able to overcome drug resistance to classical chemotherapy. These features
render the drug a promising candidate for tumor therapy especially for cancers known for their
high rates concerning therapy resistance like melanoma.
Results:  We show here that the melanoma cell line M14 is resistant to Curcumin induced
apoptosis, which correlates with the absence of any effect on NFκB signaling. We show that
CXCL1 a chemokine that is down regulated in breast cancer cells by Curcumin in an NFκB
dependant manner is expressed at variable levels in human melanomas. Yet in M14 cells, CXCL1
expression did not change upon Curcumin treatment. Following the hypothesis that Curcumin is
rapidly removed from the resistant cells, we analyzed expression of known multi drug resistance
genes and cellular transporters in M14 melanoma cells and in the Curcumin sensitive breast cancer
cell line MDA-MB-231. ATP-binding cassette transporter ABCA1, a gene involved in the cellular
lipid removal pathway is over-expressed in resistant M14 melanoma as compared to the sensitive
MDA-MB-231 breast cancer cells. Gene silencing of ABCA1 by siRNA sensitizes M14 cells to the
apoptotic effect of Curcumin most likely as a result of reduced basal levels of active NFκB.
Moreover, ABCA1 silencing alone also induces apoptosis and reduces p65 expression.
Conclusion: Resistance to Curcumin thus follows classical pathways and ABCA1 expression
should be considered as response marker.
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Bachground
The naturally occurring polyphenol Curcumin (Diferu-
loylmethane) is a major component of the rhizome of
tumeric (Curcuma longa) and commonly used as a spice in
India. It has been used for centuries as a traditional med-
icine to treat various inflammatory disorders [1,2] and has
revealed remarkable anti-tumor activity in various organs
and cell models [3-11]). offering a role as novel candidate
for chemoprevention of cancer.
In a previous study we have shown that Curcumin signif-
icantly reduces the number of metastases formed from
intracardially injected breast cancer cells [3]. The underly-
ing molecular mechanism involves the inhibition of the
survival related transcription factor nuclear factor κB
(NFκB) and its down-stream targets, the pro-inflamma-
tory cytokines CXCL1 and -2 [4]. CXCL1 and -2 are
expressed at high levels in very few breast cancers but in
many primary and metastatic melanomas (see results sec-
tion). We therefore addressed the question whether Cur-
cumin could be a possible candidate drug for the
chemoprevention of this type of cancer.
Melanoma, the most deadly form of skin cancer, is very
aggressive and resistant to present therapies. The current
treatment modalities for melanoma fail to prevent the
spread of metastasis in nearly 50% of the patients [12].
The development of new therapies is therefore required.
The use of Curcumin in in vitro models of melanoma has
so far shown promising results, inasmuch as the
melanoma cell lines responded well to the polyphenol in
terms of diminished NFκB activity, which is associated
with reduced proliferation and induction of apotosis
[13,14].
However, the cell lines used in these studies are less tum-
origenic and have a lower metastatic potential than the
highly metastatic human M14 melanoma cell line that we
use here [15-17].
Curcumin acts at least in part through diminished translo-
cation of the transcription factor NFκB [18] which is con-
stitutively active in many tumor cells. Inhibition of NFκB
activity is associated with anti-proliferative effects, as well
as with the induction of apoptosis [19,20]. Several signal
transduction pathways converge on NFκB and its regula-
tors to mediate the transcriptional control of apoptosis
and cell-cycle control [21,22]. NFκB is required for pre-
vention of cell death induced by tumor necrosis factor
alpha (TNF-alpha) and its ability to induce anti-apoptotic
genes such as bcl2 and birc5/survivin protects cancer cells
from apoptosis [23,24]. Activation of NFκB constitutes a
crucial step in tumor promotion and progression, angio-
genesis, inflammation, invasion, and metastasis [25].
In the present investigation, we show that M14 cells are
resistant to the apoptotic effects of Curcumin and demon-
strate that constitutively active pro-apoptotic NFκB can-
not be inactivated by the polyphenol in these highly
metastatic melanoma cells. As a consequence, the
polyphenol does not reduce the expression of the metas-
tasis-related pro-inflammatory cytokine CXCL1/GROα
[26], which is known to be a NFκB target [27].
Drug resistance is most often determined by over-expres-
sion of multidrug resistance genes, a superfamily of trans-
membrane proteins that act as ATP hydrolyzing cellular
transporters and are able to export a wide variety of natu-
ral and synthetic compounds from the cells (for a review
see [28]).
Here we show that resistance of M14 melanoma cells to
Curcumin is due to over-expression of the cholesterol
transporter ABCA1 and demonstrate that silencing of this
multi-drug resistance gene leads to better response of M14
cells to the polyphenol.
Materials and methods
Cell Types and Culture Conditions
M14 human melanoma cell line was cultured in RPMI-
1640 medium supplemented with fetal calf serum (10%),
gentamycin (0,1%) and L-glutamine (1%). MDA-MB-231
human breast cancer cells were grown in MEM (Eagle's)
with Earle's salts supplemented with 5% heat inactivated
fetal calf serum, 1% L-glutamine solution (200 mM), 1%
sodium pyruvate solution (100 mM), non-essential
amino acids and vitamins. Cells were grown at 37°C in a
humidified atmosphere of 5% CO2. Medium was changed
every two days.
Curcumin Treatment of Cells
Curcumin with a purity of 95% was purchased from Fluka
(Buchs, Switzerland), dissolved in 0.5 M NaOH as a 25
mM stock solution and stored at -20°C. For the use in cell
culture a 2.5 mM solution in sterile PBS was prepared.
Curcumin was applied at an end concentration of 25 μM
for all assays.
Flow Cytometric Analysis
Human M14 melanoma cells were cultivated in a 24 well-
plate and incubated with 25 μM Curcumin for various
time intervals. The cells were harvested and then treated
with (FITC)-conjugated annexin V and propidium iodide
(Annexin-V-FLUOS Staining kit from Roche, Germany)
according to the recommendations of the manufacturer.
Ten thousand events were counted for each sample. Data
were analyzed using a Flow-Cytometer (Beckman Coulter
XL-MCL, Software: System II).Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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Electrophoretic Mobility Shift Assay
M14 cells were seeded onto 150 cm2 culture dishes with
25 ml culture medium and treated for various time inter-
vals (2, 4, 6 h) with 25 μM Curcumin. Nuclear extracts
were prepared as described previously [29]. Oligonucle-
otides corresponding to the consensus sequences of NFκB
(5'-GTTAGTTGAGGGGACTTTCCCA-GGC-3') were
labeled with [alpha-32P]dATP (3000 Ci/mM) and Klenow
enzyme and were incubated with 10 μg of nuclear protein
in 20 μl of 7 mM Hepes-KOH (pH 7.9), 100 mM KCl, 3.6
mM MgCl2, and 10% glycerol on ice for 20 min. Poly [d(I-
C)] (0.05 mg/ml) was added as an unspecific competitor.
The samples were run on a 5% nondenaturing polyacryla-
mide gel in a buffer containing 25 mM Tris-HCl (pH 8.0),
190 mM glycine, and 1 mM EDTA. Gels were dried and
analyzed by autoradiography. In order to prove the specif-
icity of the probes, a 50 fold excess of unlabeled probe was
incubated with the binding reaction mixture for 45 min
on ice before adding the radiolabeled DNA fragment.
Immunocytochemistry for NF B p65 Location
The nuclear translocation of p65 was examined by immu-
nocytochemistry as described previously [30,31]. Briefly,
cells were plated on SuperFrost glass slides for adherence
and treated the next day with Curcumin. Slides were air-
dried for 1 h at room temperature and fixed with ice-cold
acetone. After brief washing in PBS, slides were blocked
with a blocking solution (Biogenex, San Ramon, CA) for
1 h and then incubated with a 1:100 dilution of rabbit
polyclonal anti-human p65 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA). After overnight incubation,
the slides were washed and then incubated with goat anti-
rabbit IgG-Alexa 594 (Invitrogen - Molecular Probes,
Carlsbad, CA) for 1 h and counter-stained for nuclei with
1  μg/ml 4',6-diamidino-2-phenylindole (DAPI) for 5
min. Stained slides were mounted with mounting
medium (Vector Labs, Burlingame, CA) and analyzed
under a fluorescence microscope with digital image cap-
ture (Leica, Bensheim, Germany).
Gene Silencing
RNA interference (RNAi) was used to generate specific
knockdowns of ABCA1 mRNA transcripts in the human
melanoma cell line M14. Small interfering RNAs targeted
to ABCA1 were purchased pre-designed (Ambion, UK). A
non-silencing fluorescein labeled siRNA (Qiagen, Hilden,
Germany) was used as control for transfection efficiency
as well as for monitoring the effect of silencing during all
experiments. Cell cultures with at least 90% transfection
efficiency were used for further studies. Transfection of
M14 cells (40% confluency) with siRNA was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the recommendations of the manufacturer.
Briefly, the transfection reagent was pre-incubated with
the siRNA Oligos either targeted to ABCA1 or to an irrele-
vant control 30 min prior to the application to the cells.
Cells were harvested at various time points between 2 h
and 24 h after transfection.
Quantitative RT-PCR
Expression data validation was performed by quantitative
real-time RT-PCR using the RNA extracted from drug- or
mock-treated cells and analysis of transcript expression
after gene silencing was performed from cells transfected
with siRNAs or a non-silencing fluorescein labeled con-
trol. RNA was extracted from cells using the RNeasy Pro-
tect Mini Kit (Qiagen, Hilden, Germany) according to the
recommendation of the manufacturer and reverse tran-
scribed as above with oligo dT primers in 20 μl final vol-
ume. All primers for the genes tested were designed using
primer3 software [32] with a Tm optimum of approxi-
mately 60°C and a product length of 100-150 nt (see
additional file 1). Real time PCR was performed on an I-
Cycler (Biorad Hercules, CA) using iQ Supermix (Biorad)
supplemented with 10 nM fluorescein (Biorad), 0.1×
Sybr-Green I (Sigma-Aldrich), 2.5 μl of cDNA (5×
diluted), 3 pmol sense and antisense primers in a final
reaction volume of 25 μl. After an initial denaturation step
of 3 min, 50 cycles of 15 sec at 95°C followed by 30 sec at
60°C were performed. Fluorescence was measured during
the annealing step in each cycle. After amplification melt-
ing curves with 80 steps of 15 sec and 0.5°C increase were
performed to monitor amplicon identity. Amplification
efficiency was assessed for all primer sets utilized in sepa-
rate reactions, and primers with efficiencies >94% were
used. Expression data were normalized on HPRT and on
RNA polymerase II (RPII) gene expression data obtained
in parallel. Relative expression values with standard errors
were obtained using Qgene software [33] and statistical
comparisons (unpaired two-tailed t-test) were performed
using Prism (GraphPad) software. Expression changes
were calculated using the mean value of normalizations
obtained using HPRT and RPII genes as references.
Protein Determination
Protein concentrations were determined by the BCA pro-
tein assay (Pierce, Oud-Beijerland, Netherlands) with
bovine serum albumin as the standard.
Western Blots
Conditioned media from Curcumin-treated (6, 15 and 24
h) and non-treated control cells were analyzed using an
antibody against CXCL1 (Dianova, Hamburg, Germany).
Equal amounts of protein were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
the amount of protein blotted onto the membranes was
visualized with Ponceau red before blocking. Following
electrophoretic separation by sodium dodecyl sulfate-Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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polyacrylamide gel electrophoresis, proteins were elec-
troblotted on nitrocellulose membranes (Whatman,
Brentford, UK). The membranes were blocked in 5% non-
fat milk (Merck, Darmstadt, Germany) overnight at 4°C.
The first antibody was incubated for 1 h at room temper-
ature. Thereafter, membranes were washed in tris buffered
saline with Tween buffer, and a further incubation was
carried out with a peroxidase-conjugated antibody (Dako,
Hamburg, Germany) for 1 h at room temperature. The
enhanced chemiluminescence system was used for visual-
ization of the protein bands as recommended by the man-
ufacturer (GE Healthcare, Little Chalfont, UK).
Apoptosis Assay
Apoptotic cell death was determined by an enzyme-linked
immunoassay (Cell Death Detection ELISA PLUS, Roche)
to detect fragmented DNA and histones (mononucleo-
somes and oligonucleosomes). Human melanoma cells
M14 were seeded on 96-well plates and silenced by trans-
fection with siRNAs directed against ABCA1 or a nonsense
targeted sequence in combination with 25 μM Curcumin
or without treatment. Lysates prepared from the cells were
processed following the instructions of the manufacturer
Microarray gene expression analyses
Total RNA was extracted from M14 melanoma and MDA-
MB-231 breast cancer cells as described above. Sample
preparation, hybridization and scanning of Affymetrix
(Santa Clara, CA, USA) HGU133plus2 arrays were per-
formed following the instructions given by the provider.
Raw expression data were pre-processed using the
GCRMA algorithm implemented in R/Bioconductor.
Genes with expression values below an unlogged intensity
of 100 in both cell lines were not considered. Significance
Analysis of Microarrays [34] was used for statistical evalu-
ation of differential gene expression values.
Micorarray gene expression dataset GSE7553 [35] were
obtained form Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo/. The expression values pub-
lished by the authors were used without further process-




Human M14 melanoma cells treated for up to 24 h with
25 μM Curcumin show only very weak signs of apoptosis.
Flow cytometry analysis reveal that only a small propor-
tion of melanoma cells undergo early apoptosis in terms
of translocation of the membrane phospholipid phos-
phatidylserine from the inner to the outer leaflet of the
plasma membrane, where it becomes accessible to
annexin V staining (green). Additionally less than 1% of
the cells undergo irreversible apoptosis visualized here by
propidium iodide staining (red). In consequence the
staining intensities for both annexin V and propidium
iodide are very weak indicating that the melanoma cells
are very resistant to Curcumin in terms of apoptosis (fig-
ure 1). Only very few cells reach late apoptosis as indi-
cated by weak propidium iodide staining. In contrast to
the here presented data on melanoma cells, the human
breast cancer cells MDA-MB-231 cells, who respond very
well to Curcumin, undergo early and late apoptosis (pub-
lished by us previously [3].
Curcumin has no Effect on NF B Signaling in Melanoma 
Cells
NFκB signaling pathway is an important signal transduc-
tion pathway that plays a critical role in cell survival and
apoptosis. As we observed only weak effects of Curcumin
on apoptosis in M14 cells we investigated the status of
NFκB/p65 in these cells after treatment with Curcumin.
Nuclear extracts from Curcumin treated and untreated
M14 cells were applied to electrophoretic mobility shift
assays (EMSA) where the binding of transcription factors
is revealed by the retarded electrophoretic migration of
radioactively labeled oligonucleotides of the specific
binding sequence (figure 2a). The specificity of the bind-
ing was assessed by addition of a 50 fold excess of cold oli-
gonucleotides that abolished the band shifts observed
(figure 2a; lane 5). Addition of an unrelated mutant oligo-
nucleotide had no effect on NFκB binding (data not
shown).
Curcumin treatment for 2, 4, and 6 h of M14 cells (figure
2a, lanes 2, 3, and 4,) does not show any reduction in the
specific bands for the transcription factor NFκB in com-
parison to untreated cells (lane 1) indicating that Curcu-
min has no effect on the NFκB pathway in these cells.
Localization of the NFκB subunit p65 was monitored by
immunofluorescence analyses using specific antibodies
(figure 2b). M14 cells did not respond to Curcumin treat-
ment and p65 was located in the nucleus as well as in the
cytoplasm without any difference between treated and
untreated control cells. DNA in the nuclei was stained
with DAPI (figure 2b pictures A and D)
CXCL1 is highly expressed in many primary and metastatic 
melanomas
We previously published, that the metastasis-related pro-
inflammatory cytokines CXCL1 and -2 are down-regu-
lated upon Curcumin treatment. The direct correlation
between NFκB and CXCL1 and -2 expressions implies that
the two cytokines are NFκB targets [4]. CXCL1 is also
present in several metastasis signatures [26,36,37]. We
wished to understand whether CXCL1 may play a role in
melanoma so we analyzed published microarray gene
expression data [35]. CXCL1 is strongly and highly differ-Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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entially expressed in primary and metastatic melanoma
and in other skin cancers (figures 3a and 3b). During the
progression from normal human melanocytes (n = 1)
over melanoma in situ (n = 2) and primary melanoma (n
= 14) to metastatic melanoma (n = 41) there is a signifi-
cant trend of increase of CXCL1 gene expression (p =
0.0237).
Given the potential role in melanoma progression, we
analyzed whether the lack of effect of Curcumin on NFκB
is transferred to the downstream target, CXCL1.
As determined by qRT-PCR, treatment of M14 melanoma
cells with Curcumin for several time periods (2, 4, 6, 15
and 24 h) did not affect CXCL1 expression (figure 3c).
CXCL2 was not expressed in M14 melanoma cells (data
not shown). These results demonstrate that M14 cells are
resistant to Curcumin on the level of transcriptional regu-
lation by NFκB as well as on the level of its downstream
targets.
These results were true also for the respective protein level.
Western Blot results (figure 3d) revealed that M14
melanoma cells treated for several time periods (6 h, 15 h,
24 h) with Curcumin (lanes indicated with "+") did not
express and secrete less CXCL1 into their conditioned
media than their respective un-treated control cells (lanes
indicated with "-").
Thereby we were able to demonstrate that Curcumin does
not alter the expression of CXCL1 neither on transcript
nor on protein level.
Expression of multidrug resistance genes and cellular 
transporters
In order to identify Curcumin resistance mechanisms we
compared expression levels of known multi drug resist-
ance genes and cellular transporters under the hypothesis,
that Curcumin is rapidly removed from the resistant cells.
For this purpose we performed microarray gene expres-
sion profiling using Affymetrix whole genome arrays
(HGU133plus2) for M14 cells as well as for the strongly
Curcumin sensitive breast cancer cell line MDA-MB-231.
We identified differential expression for several ATP-bind-
ing cassette transporter genes that are expressed above the
intensity threshold of 100 (figure 4a, data are shown for
all probesets for each gene) and for correlated expression
levels in the two cell lines (figure 4b). Over-expression of
these genes may determine drug resistance and therefore,
we tried to identify those genes that are over-expressed in
M14 cells. ABCA1, a transporter that is involved in the cel-
lular lipid removal pathway is the most highly over-
expressed transporter in M14 cells as compared to Curcu-
min sensitive MDA-MB-231 cells. Over-expression is
revealed by both probesets specific for this gene. ABCA1 is
among the genes that are differentially expressed in the
two cell lines in a statistically significant manner as ana-
lyzed by a permutation (Signficance Analysis of Microar-
ray; [34]).
Involvement of ABCA1 in Curcumin induced resistance
After we had seen that ABCA1 is among the most differen-
tially expressed genes between non-resistant MDA-MB-
231 and resistant M14 cells, we analyzed the functional
involvement of this ATP-binding cassette transporter in
the Curcumin induced resistance on NFκB signaling and
apoptosis.
We transiently knocked down ABCA1 in M14 cells by
siRNA induced gene silencing and studied the effect of
Curcumin on p65 (figure 5A), the apoptosis related fac-
tors bcl2 (figure 5B) and survivin (figure 5C) and cell
death (increase of free nucleosomes, figure 5D) in a series
of double modulation experiments.
Silencing of the multidrug resistance gene ABCA1 led to a
reduction of p65 expression down to 50% of the original
level already after 15 h (figure 5A, M14ABCA1si (tringle
up)). The simultaneous treatment with 25 μM Curcumin
further reduced p65 expression down to about 15% (p <
0.01) of the initial value after 24 h treatment (figure 5A,
M14ABCA1si Cur (diamond)). It is clearly visible that
ABCA1 silencing restores the effect of Curcumin on NFκB
p65 subunit expression. Approximately 40% of this effect
Melanoma Cells are resistant to Curcumin induced Apopto- sis Figure 1
Melanoma Cells are resistant to Curcumin induced 
Apoptosis. Fluorescence micrographs of annexin V and pro-
pidium iodide stained human melanoma cells show that Cur-
cumin induces only weakly apoptosis in M14 cells as 
evidenced by a very faint annexin V positive (green) staining. 
After 24 h of Curcumin treatment only very few M14 cells 
reach irreversible apoptosis and thereby a propidium iodide 
positive stage (red).Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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can be attributed to Curcumin. Yet ABCA1 silencing alone
also reduces p65 expression, however, this effect is statis-
tically not significant (p > 0.05).
Well in line with the effect of Curcumin on p65, expres-
sion of the NFκB regulated anti-apoptotic factors bcl2 and
survivin was impaired after ABCA1 silencing. Bcl2 expres-
sion was reduced 10% in ABCA1-silenced cells 24 h after
transfection with siRNA (figure 5B, M14ABCA1si (triangle
down)). Treatment of M14 cells carrying the ABCA1
knock-downs with 25 μM Curcumin led to a significant
inhibition of bcl2 expression of about 35% with p < 0.001
(figure 5B, M14ABCA1si Cur (diamond)). Hence Curcu-
min reduces bcl2 expression in M14 cells transfected with
ABCA1 siRNAs by about 25%. Expression of survivin was
diminished upon silencing of ABCA1 in M14 cells to
about 50% of the basic value 24 h after transfection with
siRNAs (figure 5C, M14ABCA1si (triangle down)). The
addition of 25 μM Curcumin to ABCA1 silenced cells fur-
ther reduced survivin expression significantly in M14 cells
down to about 40% (p < 0.01) of initial expression levels
(figure 5C, M14ABCA1si Cur (diamond)). Accordingly
Curcumin treatment diminishes survivin expression in
ABCA1 silenced M14 cells to 10%.
Apoptosis as measured by means of increased numbers of
free nucleosomes in cell lysates was induced in ABCA1
silenced M14 cells 24 h after transfection with siRNAs (fig-
ure 5D, M14ABCA1si (triangle down)). Curcumin treat-
ment of the ABCA1 silenced M14 cells dramatically
induced apoptosis already after 2 h with increasing effect
up to 24 h with a p-value of p < 0.01 (figure 5D,
M14ABCA1si Cur (diamond)).
Transfection of an unspecific nonsilencing siRNA control
alone (M14nonsi) alone or in combination with 25 μM
Curcumin (M14nonsi Cur) did neither alter the expres-
sion of p65, bcl2 and survivin nor induce apoptosis in
M14 cells (figure 5A, B, C, D, M14nonsi (triangle up),
M14nonsi Cur (square))
Statistical evaluation of the results concerning the effects
of ABCA1 on response to Curcumin (summarized in table
1) revealed that knocking-down the multidrug resistance
gene alone already inhibits expression of the NFκB subu-
nit p65 and the survival factors bcl2 and survivin and
induces apoptosis in melanoma cells. However these
effects are not statistically significant. Only the combina-
tion of knocking down ABCA1 together with simultane-
ous application of Curcumin results in a statistically
highly significant response in terms of apoptosis.
Taken together, resistance of M14 cells to Curcumin can
be overcome by silencing of the ATP-binding cassette
transporter ABCA1, which in turn leads to a reduction of
p65, bcl2 and survivin and, as a consequence, to an induc-
tion of apoptosis. This is the first indication that trans-
porters involved in the lipid metabolism are linked to
NFκB and cell survival.
Curcumin does not down-regulate NFκB in Melanoma cells Figure 2
Curcumin does not down-regulate NFκB in Melanoma cells. a) Analysis of the binding of nuclear proteins from M14 
melanoma cells to an oligo specific to the p65 binding site present in various promoters by EMSA revealed that Curcumin 
treatment did not alter p65 activity. There was no clear difference between the bands of treated (lane 2: 2 h; lane 3: 4 h; lane 4: 
6 h) and untreated (lane 1) M14 cells using 10 μg of nuclear protein incubated with the 32P-labeled oligonucleotide. b) Immun-
ofluorescent NFκB translocation assays using specific antibodies against the p65 unit show that NFκB is located both in the 
nucleus and the cytoplasm without any difference between Curcumin treated (lower panel) and untreated (upper panel) cells. 
(A, F: DAPI; B, G: p65; C, H: DAPI&p65). Experiments were performed in triplicates. Magnification ×200Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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Discussion
Among the plant derived products, Curcumin is perhaps
the most interesting for long term anti-cancer chemopre-
vention. Much evidence has accumulated on the preven-
tive effects of the polyphenol and the molecular pathways
of its actions have been unraveled to considerable detail.
Anti-proliferative and pro-apoptotic effects are most likely
linked to the inhibition of pro-inflammatory and anti-
apoptotic NFκB signaling, a now well established func-
tion of the compound. We have recently shown that Cur-
cumin inhibits the formation but not the growth of
metastases in an in vivo model of immunodeficient mice
[3]. However, the anti-metastatic activity of the natural
polyphenol cannot be completely ascribed to its pro-
apoptotic activity. Curcumin apparently also influences a
network of pro-metastatic players that depend on NFκB
and in this context the inflammatory cytokines CXCL1
and -2 (GROα and β) appear to play a crucial role inas-
much as they influence the expression of several other
pro-metastatic genes including CXCR4 [4]. The impor-
a) Gene expression values of CXCL1 in normal skin (NS), normal human melanocytes (NHM), melanomas in situ (MIS), pri- mary (PM) and metastatic (MM) melanomas were obtained from oligonucleotide microarray data Figure 3
a) Gene expression values of CXCL1 in normal skin (NS), normal human melanocytes (NHM), melanomas in 
situ (MIS), primary (PM) and metastatic (MM) melanomas were obtained from oligonucleotide microarray 
data. The expression values of single samples (symbols) and the mean expression level (lines) are reported. b) CXCL1 expres-
sion during progression from normal human melanocytes (1) to melanoma in situ (2), primary (3) and metastatic (4) melanoma. 
There is a significant trend to increased CXCL1 expression during melanoma progression. c) qRT-PCR analysis of M14 
melanoma cells shows that treatment with Curcumin for several time periods (2, 4, 6, 15 and 24 h) did not effect CXCL1 
expression. d) Well in line with RT-PCR results, CXCL1 expression visualized here by Western Blots of cell culture superna-
tants was not altered in M14 cells treated for several time intervals (6 h, 15 h, 24 h) with Curcumin (lanes indicated with "+") 
versus respective un-treated (lanes indicated with "-") cells. Equal amounts of total protein were applied per lane and experi-
ments were performed in triplicate.Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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Expression of ABC genes in M14 cells as compared to the Curcumin sensitive cell line MDA-MB-231 Figure 4
Expression of ABC genes in M14 cells as compared to the Curcumin sensitive cell line MDA-MB-231. Gene 
expression was analyzed using Affymetrix HU133plus2 arrays in M14 and MDA-MB-231 cells. The ratio of intensity levels of all 
probesets encoding ABC genes above the arbitrary threshold of 100 in M14 versus MDA-MB-231 cells were plotted on a log2 
scale (A). All probesets encoding for ABC genes were used for a correlation plot (B).Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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tance of CXCL1 in the process of metastasis has recently
been reported and is also reflected by its presence in sev-
eral metastasis signatures [26,37]. The lung metastasis sig-
nature presented by Minn and coworkers has been
developed using a CXCL1 and -2 positive cell line, yet in
human breast cancers, CXCL1 and -2 are not expressed at
considerable levels, and in only a small minority of cases
[37].
We show here that CXCL1 is strongly (and highly varia-
bly) expressed in human primary and metastatic melano-
mas as well as other skin cancers and several other groups
Involvement of ABCA1 in Curcumin induced resistance Figure 5
Involvement of ABCA1 in Curcumin induced resistance. The effect of Curcumin on p65 (A), the apoptosis related fac-
tors bcl2 (B) and surviving (C) and cell death (increase of free nucleosomes, D) was analyzed in a series of double modulation 
experiments. Silencing of the multidrug resistance gene ABCA1 led to a reduction of p65 expression down to 50% of the orig-
inal level already after 15 h (panel A, M14ABCA1si (triangle down)). The simultaneous treatment with 25 μM Curcumin further 
reduced p65 expression down to about 15% of the initial value after 24 h treatment (panel A, M14ABCA1si Cur (diamond)). 
Expression of the NFκB regulated anti-apoptotic factors bcl2 and survivin was reduced after ABCA1 silencing: bcl2 expression 
was reduced 10% in ABCA1-silenced cells 24 h after transfection with siRNA (panel B, M14ABCA1si (triangle down)). Treat-
ment of M14 cells carrying the ABCA1 knock-downs with 25 μM Curcumin led to a significant reduction of bcl2 expression of 
about 35% with (panel B, M14ABCA1si Cur (diamond)). Hence Curcumin reduces bcl2 expression in M14 cells transfected 
with ABCA1 siRNAs by about 25%. Expression of survivin was diminished upon silencing of ABCA1 in M14 cells to about 50% 
of the basic value 24 h after transfection with siRNAs (panel C, M14ABCA1si (triangle down)). The addition of 25 μM Curcu-
min to ABCA1 silenced cells further reduced survivin expression significantly in M14 cells down to about 40% of initial expres-
sion levels (figure 5C, M14ABCA1si Cur (diamond)). Accordingly Curcumin treatment diminishes survivin expression in 
ABCA1 silenced M14 cells to 10%. Apoptosis as measured by means of increased numbers of free nucleosomes in cell lysates 
was induced in ABCA1 silenced M14 cells 24 h after transfection with siRNAs (panel D, M14ABCA1si (triangle down)). Curcu-
min treatment of the ABCA1 silenced M14 cells dramatically induced apoptosis already after 2 h with increasing effect up to 24 
h (panel D, M14ABCA1si Cur (diamond)). Transfection of an unspecific nonsilencing siRNA control alone (M14nonsi) or in 
combination with 25 μM Curcumin (M14nonsi Cur) did neither alter the expression of p65, bcl2 and survivin nor induce apop-
tosis in M14 cells (panels A, B, C, D, M14nonsi (triangle up), M14nonsi Cur (square))Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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have underlined the importance of CXCL1 in melanoma
progression pointing to its tumorigenic and angiogenic
effects [38] and to tumor-host interactions [39]. With this
in mind we set out to test the potential of Curcumin as
chemopreventive drug for melanoma.
Our results demonstrate that the highly metastatic
melanoma cell line M14 is, however, relatively resistant to
the effects of Curcumin, in particular if compared to what
we have observed for breast cancer cells [3,4]. Even after
48 hours only early apoptosis can be observed and very
few cells are irreversibly committed to cell death. This
clearly correlates with the lack of effects on NFκB/p65
translocation and DNA binding capacity to the NFκB pro-
moter presence in nuclear extracts. As a consequence, we
saw, that expression of CXCL1 is not affected by the
polyphenol. To our best knowledge, this is the first
description of resistance to Curcumin, a drug that has
itself been reported to be able to overcome drug resistance
to classical chemotherapy [40-43]. Drug resistance is in
most cases a result of over-expression of cellular transport-
ers that are able to extrude the compound in a short time
thereby avoiding the accumulation within the cell to
active concentrations [28]. We therefore created and ana-
lyzed gene expression profiles of M14 cells in comparison
to the highly sensitive cell line MDA-MB-231. Most of the
gene expression differences between the two cell lines can
be attributed to their different origin of tissue; yet we con-
sidered multiple drug resistance genes that are over-
expressed in M14 cells as compared to the breast cancer
cell line to be the reason for the resistance against Curcu-
min. Thereby we were able to identify essentially a single
ATP-binding cassette transporter gene, ABCA1 to be
responsible for the lack of response to Curcumin in M14
melanoma cells. Moreover we have previously analyzed
the breast cancer cell lines MCF-7 and MDA-MB-468 and
found that both, similar to MDA-MB-231 cells, are Curcu-
min sensitive and do not express ABCA1 (our unpub-
lished data).
Here we show that silencing of ABCA1 by small interfer-
ing RNAs restores Curcumin sensitivity in M14 cells in
terms of apoptosis, proliferation, transcriptional effects
on NFκB/p65 transcription and CXCL1 expression in M14
cells.
ABCA1 is a lipid transporter that plays an important role
in cholesterol efflux and thereby prevents toxicity associ-
ated with cholesterol overload. Moreover its activity is
essential for formation of high-density lipoprotein (HDL)
particles in vivo and mutations of ABCA1 lead to Tangier
disease, an autosomal recessive trait characterized by HDL
deficiency [44,45]. Low plasma HDL is associated with
type 2 diabetes and metabolic syndrome [46,47] suggest-
ing that ABCA1 contributes to this complication. Meta-
bolic syndrome and type 2 diabetes are strongly correlated
with therapy resistance and increased cancer risk [48]. We
show here that the ability of Curcumin to induce apopto-
Table 1: Statistical evaluation of the results concerning the effects of ABCA1 on response to Curcumin
p65
Bonferroni's Multiple Comparison Test Mean Diff. t P value 95% CI of diff
435nonsi vs 435nonsi Cur 1,393 0,2931 P > 0.05 -11.03 to 13.81
435nonsi vs 435ABCA1si 12,22 2,57 P > 0.05 -0.2006 to 24.64
435nonsi vs 435ABCA1si Cur 18,4 3,872 P < 0.01 5.985 to 30.82
bcl2
Bonferroni's Multiple Comparison Test Mean Diff. t P value 95% CI of diff
M14nonsi vs M14nonsi Cur -0,00009025 0,4383 P > 0.05 -0.0006282 to 0.0004477
M14nonsi vs M14ABCA1si 0,0004488 2,18 P > 0.05 -0.00008914 to 0.0009868
M14nonsi vs M14ABCA1si Cur 0,0009655 4,689 P < 0.001 0.0004275 to 0.001503
Survivin
Bonferroni's Multiple Comparison Test Mean Diff. t P value 95% CI of diff
M14nonsi vs M14nonsi Cur -0,00006799 0,1184 P > 0.05 -0.001568 to 0.001432
M14nonsi vs M14ABCA1si 0,001349 2,349 P > 0.05 -0.0001513 to 0.002849
M14nonsi vs M14ABCA1si Cur 0,002271 3,955 P < 0.01 0.0007706 to 0.003770
Apoptose
Bonferroni's Multiple Comparison Test Mean Diff. t P value 95% CI of diff
M14nonsi vs M14nonsi Cur 0,000869 0,005529 P > 0.05 -0.4193 to 0.4210
M14nonsi vs M14ABCA1si -0,07965 0,5067 P > 0.05 -0.4998 to 0.3405
M14nonsi vs M14ABCA1si Cur -0,688 4,377 P < 0.01 -1.108 to -0.2679
Knocking-down the multidrug resistance gene alone already inhibits expression of the NFκB subunit p65 and the survival factors bcl2 and survivin 
and induces apoptosis in melanoma cells. However these effects are not statistically significant. Only the combination of knocking down ABCA1 
together with simultaneous application of Curcumin results in a statistically highly significant response in terms of apoptosis.Molecular Cancer 2009, 8:129 http://www.molecular-cancer.com/content/8/1/129
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sis and to act on NFκB is restored by knocking down
ABCA1 in treatment resistant M14 melanoma cells. Inter-
estingly, silencing of the ABCA1 transporter alone, in the
absence of Curcumin already induces apoptosis, yet to a
lesser, statistically not significant extent. Future studies
will show whether over-expression of the transporter and
eventually others of the family in therapy sensitive tumor
cells, activate the NFκB pathway and whether this might
contribute to a more aggressive growth of multiple drug
resistant cancers.
We show here that drug resistance is an important issue
also for chemoprevention and future clinical trials with
Curcumin should consider testing of ABCA1 expression as
a potential response predictor. This is particularly impor-
tant since the introduction of Curcumin into clinical pre-
vention strategies most probably starts from the
accumulation of data on effects in late stage disease
patients who might carry metastases that over-express
ABCA1. In the majority of primary and metastatic
melanomas ABCA1 is highly expressed [35]. Melanoma is
therefore most likely not a good target for Curcumin treat-
ments unless patients are selected on the base of ABCA1
expression.
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